Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Tria

• Autores: Andrew X. Zhu, Masatoshi Kudo, Eric Assenat, Stéphane Cattan
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 312, Nº. 1, 2014, págs. 57-67
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • Importance Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma.

    Objective To assess the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed.